Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Hematologic Oncology Update

Good afternoon, everyone. I'm Neil Love from Research to Practice, and welcome to Consensus or Controversy. Today, we're going to talk about the management of myelofibrosis. We have a great faculty today, Professor Claire Harrison from the Geys and St. Thomas NHS Foundation Trust in London, United Kingdom, and Dr. Rajit Rampal from the Memorial Sloan-Kettering Cancer Center in New York City.

We also recruited four other investigators, Drs. Bose, Kukendahl, Mascarenis, and Jacob, to take a survey that you're going to find of great, great interest. This was a big day for myelofibrosis at ASCO this morning. Today, we're here to talk about myelofibrosis, and as is all of our programs nowadays, we will be talking about the use of unapproved agents and regimens.

So check out the package inserts of the various products that we talk about today. We're just finishing up. This is the 14th program we've done since Friday. This is a wild ASCO. We never tried to do this before. It went great. We had 12 different investigators moderating meetings. This is like what you call see one, do one, teach one.

They did a great job, and thanks to our staff, like amazing, Catherine, Kirsten, Kevin, Sylvia, Christina, and many, many more people. I can't believe that we actually pulled this off, so congratulations. But here we are now at the end, and we never imagined when we planned this that this is going to be as exciting as it is,

because this morning was a myelofibrosis oral session, and as you probably know, there's a big Phase III trial presented with Salonexer. We're going to talk about that in a little bit. But first, I want to just take a breath. Here's where we're heading. We're going to start out.

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.